[go: up one dir, main page]

AU2001275537A1 - N-and o-substituted 4-(2-(diphenylmethoxy)-ethyl)-1-((phenyl)methyl)piperidine analogs and methods of treating cns disorders therewith - Google Patents

N-and o-substituted 4-(2-(diphenylmethoxy)-ethyl)-1-((phenyl)methyl)piperidine analogs and methods of treating cns disorders therewith

Info

Publication number
AU2001275537A1
AU2001275537A1 AU2001275537A AU7553701A AU2001275537A1 AU 2001275537 A1 AU2001275537 A1 AU 2001275537A1 AU 2001275537 A AU2001275537 A AU 2001275537A AU 7553701 A AU7553701 A AU 7553701A AU 2001275537 A1 AU2001275537 A1 AU 2001275537A1
Authority
AU
Australia
Prior art keywords
diphenylmethoxy
phenyl
ethyl
substituted
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275537A
Inventor
Aloke K. Dutta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Original Assignee
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University filed Critical Wayne State University
Publication of AU2001275537A1 publication Critical patent/AU2001275537A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AU2001275537A 2000-06-20 2001-06-14 N-and o-substituted 4-(2-(diphenylmethoxy)-ethyl)-1-((phenyl)methyl)piperidine analogs and methods of treating cns disorders therewith Abandoned AU2001275537A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21292100P 2000-06-20 2000-06-20
US60212921 2000-06-20
PCT/US2001/040964 WO2001098266A2 (en) 2000-06-20 2001-06-14 N-and o-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating cns disorders therewith

Publications (1)

Publication Number Publication Date
AU2001275537A1 true AU2001275537A1 (en) 2002-01-02

Family

ID=22792949

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275537A Abandoned AU2001275537A1 (en) 2000-06-20 2001-06-14 N-and o-substituted 4-(2-(diphenylmethoxy)-ethyl)-1-((phenyl)methyl)piperidine analogs and methods of treating cns disorders therewith

Country Status (3)

Country Link
US (3) US6995268B2 (en)
AU (1) AU2001275537A1 (en)
WO (1) WO2001098266A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515131B2 (en) * 2000-02-22 2003-02-04 Biostream Therapeutics, Inc. Imagining agents for diagnosis of Parkinson's disease
US8211916B2 (en) * 2000-06-20 2012-07-03 Wayne State University N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith
US6995268B2 (en) * 2000-06-20 2006-02-07 Wayne State University N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating CNS disorders therewith
US20060122263A1 (en) * 2003-03-28 2006-06-08 Dutta Aloke K Tri-substituted 2-benzhydryl-5-benzlamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives
US7531555B2 (en) 2003-10-01 2009-05-12 University Of Florida Research Foundation, Inc. Compositions and methods for selective inhibition of nicotine acetylcholine receptors
US7915433B2 (en) 2004-04-16 2011-03-29 Wayne State University Tri-substituted 2-benzhydryl 5-benzlamino-tetrahydro-pyran-4-OL and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-OL analogues, and novel 3,6 disubstituted pyran derivatives
JP5142529B2 (en) 2004-09-30 2013-02-13 イビデン株式会社 Honeycomb structure
JP5142532B2 (en) * 2004-11-26 2013-02-13 イビデン株式会社 Honeycomb structure
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
AR061265A1 (en) * 2006-06-08 2008-08-13 Speedel Experimenta Ag PIPERIDINS 2,5- DISUSTITUTED
CA2932121A1 (en) 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
WO2016100823A1 (en) * 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU598750B2 (en) 1985-09-27 1990-07-05 Mitsubishi Chemical Corporation Phenylalanine derivative and proteinase inhibitor
FI904441A7 (en) 1989-09-12 1991-03-13 Hoechst Ag Amino acid derivatives having renin-inhibiting properties, methods for their preparation, materials containing them and their use
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
GB9000301D0 (en) * 1990-01-06 1990-03-07 Pfizer Ltd Piperidine & pyrrolidine derivatives
US5300499A (en) 1992-09-02 1994-04-05 Allergan, Inc. 5-substituted 3-thiophene sulfonamides as antiglaucoma agents
JPH09249566A (en) 1996-03-19 1997-09-22 Takeda Chem Ind Ltd Piperidine-containing chemokine receptor antagonist
HUP0001285A3 (en) 1997-05-08 2000-10-30 Smithkline Beecham Corp Philap Pyrrolidine derivatives as protease inhibitors, process for producing them and pharmaceutical compositions containing them
ID24475A (en) * 1997-11-18 2000-07-20 Teijin Limeted Cs AMINIC CYCLICS AND ITS USE AS DRUGS
BR0010308A (en) * 1999-05-06 2002-01-08 Neurogen Corp Compound, pharmaceutical composition, use of a compound, and, methods for treating a disease or disorder associated with pathogenic agonism, reverse agonism or antagonism of the gabaa receptor, to locate gabaa receptors in a tissue sample, to inhibit binding of a benzodiazepine compound to a gabaa receptor and to alter the signal transduction activity of gabaa receptors, and packaged pharmaceutical composition
US6995268B2 (en) * 2000-06-20 2006-02-07 Wayne State University N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating CNS disorders therewith

Also Published As

Publication number Publication date
US20100016600A1 (en) 2010-01-21
US7595331B2 (en) 2009-09-29
WO2001098266A3 (en) 2002-04-04
US6995268B2 (en) 2006-02-07
US20050154021A1 (en) 2005-07-14
WO2001098266A2 (en) 2001-12-27
US20030225133A1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
AU2001275537A1 (en) N-and o-substituted 4-(2-(diphenylmethoxy)-ethyl)-1-((phenyl)methyl)piperidine analogs and methods of treating cns disorders therewith
IL137149A0 (en) 4-(2-keto-1-benzimidazolinyl) piperidine compounds as orl1-receptor agonists
IL115315A0 (en) Synthesis of 3-(4-(2-aminoethoxy)-benzoyl)-2-aryl-6-hydroxybenzo (b) thiophenes
IL150813A0 (en) Substituted glutarimides and use thereof il-12 production inhibitors
EP1171078A4 (en) COMPOSITIONS AND METHODS ACTING ON THE CHOLESTEROL RATE OF HIGH DENSITY LIPOPROTEINS (HDL) AND APOLIPOPROTEINS AI, ON THE CHOLESTEROL RATES OF VERY LOW DENSITY LIPOPROTEINS (VLDL) AND ON THE CHOLESTEROL RATE OF LIPOPROTEINS (LDL)
HUP0101737A3 (en) Methods and compositions for pulmonary and nasal administration of raloxifene
HU9603237D0 (en) Kristalline hydrochloride of (r)-(-)-2-{n-[4-(1,1-dioxydo-3-oxo-2,3-dihydro-benzisothiazo-2-yl)-butyl]-amino-methyl}-chromane
ID28953A (en) 4- (AMINOMETYL) -PIPERIDINE OF BENZAMIDE TO TREAT GASTROINTESTINAL DISORDERS
SG127737A1 (en) Piperidine and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
GB0031145D0 (en) Compounds that effect cd83 expression pharmaceutical compositions comprising said compounds and methods for identifying said compounds
SI1217002T1 (en) 2-(4-pyridinyl)-benzofurans as metalloprotease inhibitors
HUP9800511A3 (en) Phosphorylized derivatives of 4-{4-[4-(hydroxy-diphenyl)-1-pipe
ITBO20010102A0 (en) METHOD AND UNIT FOR THE FORMATION OF A TOBACCO CORD
AU2002220372A1 (en) Method for screening for inhibitors of alzheimer's disease
ITBO20000510A0 (en) EQUIPMENT AND METHOD FOR CONSTRUCTION OF TRACHEOSTOMY
AU4595100A (en) ((e),3(r))-enantiomer of 4-(3-chloro -4-cyanophenyl) -1-(p- methylsulphonyl -phenylsulphonyl) -2-trifluoromethylbut -trans-3-en-ol
HUP0303418A3 (en) Inhibitors of papilloma virus
ITMI20002189A0 (en) PROCEDURE FOR CONTROLLING ACCESS TO A TELEMATIC NETWORK
AU5531001A (en) Stabilized formulations of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy)phenoxy)-2-(4-methoxyphenyl) benzo(B)thiophene and salts thereof
HUP0401039A3 (en) Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof
EE200000638A (en) Reduced particle size form of 1- (6-chloronaphth-2-ylsulfonyl) -4- [4- (4-pyridyl) benzoyl] -piperazine
FI964114L (en) New crystalline forms of 1-(5-methanesulfonamidoindolyl-2-carbonyl)-4-(3-(1-methylethylamino)-2-pyridinyl)piperazine
HUP0105124A3 (en) 1-(6-methylpyridine-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone and method for its preparation
EA200000931A1 (en) ANALGETIC TOOL "TETRALGIN" AND METHOD FOR ITS OBTAINING
NO20013498D0 (en) 1- (Methylpyridin-3-yl) -2- [4- (methylsulfonyl) phenyl] ethanone and process for its preparation